LBPH AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
LBPH Current Performance
4.41%
Longboard pharmaceuticals inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to LBPH
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
PYPD | Polypid ltd | 1 | 2 | 2 | 1 | 1 | |
TCRT | Alaunos therapeutics inc | 2 | 2 | 2 | 1 | 1 | |
ELUT | Elutia inc | 1 | 5 | 2 | 1 | 1 | |
INO | Inovio pharmaceuticals inc | 2 | 4 | 2 | 1 | 1 | |
XLO | Xilio therapeutics inc | - | 3 | 3 | 1 | 1 |
- PYPD Polypid ltdValue 1Trend 2Swing Trading 2Whale Interest 1Dividend 1See more
LBPH Profile
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.